RLX has shown efficacy against pancreatic adenocarcinoma growth through ERβ and the IL-6/gp130/STAT3 signaling pathway interference in PDAC cell line (Pozios et al., 2021). Here, ESR2 is linked to pancreatic adenocarcinoma.